ClinicalTrials.gg
CompletedNCT02532998Updated Mar 29, 2017Results posted

A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects

A Phase 1 interventional study of AZD9977 oral suspension and AZD9977 placebo oral suspension in Pharmacodynamics and Healthy Subjects, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-29.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

This is a Phase I, Randomized, Single-Blind, Crossover Study to Assess the Pharmacodynamics of AZD9977 following Single-Dose administration to healthy male subjects

Read the detailed description

This study will be a phase I study to assess the pharmacodynamics of AZD9977 following single-dose administration to healthy male subjects. It is a single-blind (with regards to AZD9977 and AZD9977 Placebo), randomized, four-treatment, four-period crossover design, with a potential 5th and 6th randomized cross-over treatment period. In this study eplerenone is used as a positive control and fludrocortisone will be used as a challenge agent. In addition the safety, tolerability and pharmacokinetics will be assessed.

02

Conditions studied

  • Pharmacodynamics
  • Healthy Subjects

Keywords

  • Pharmacodynamics
  • AZD9977
  • Safety
  • Tolerability
  • Pharmacokinetics
  • Eplerenone
  • Fludrocortisone
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated written prior to any study specific procedures.
  2. Healthy male subjects aged 18 to 50 years with suitable veins for cannulation or repeated venipuncture.
  3. Male subjects must accept to comply with the restrictions for sexual activity provided to them.
  4. Have a (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.
  5. Optional: Provision of signed and dated written informed consent for genetic research.

    Note: Participation in exploratory biomarker research is mandatory. If a subject declines to participate in the genetic component of the study, there will be no penalty or loss of benefit to the subject. The subject will not be excluded from other aspects of the study described in this protocol.

  6. Able to understand, read and speak the English language.

Exclusion criteria

Exclusion criteria

  1. History of any disease or disorder which, in the opinion of the investigator, may either put the potential subject at risk because of participation in the study, or influences the results or the potential subject's ability to participate in the study.
  2. History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  3. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of first dosing with medicinal product (IMP).
  4. Any clinically significant abnormalities in hematology, clinical chemistry or urinalysis results, as judged by the investigator.
  5. Abnormal findings in vital signs, after 10 minutes resting in the supine position, defined as any of the following:

    • Systolic blood pressure (SBP) \< 90 mmHg or ≥ 140 mmHg
    • Diastolic blood pressure (DBP) \< 50 mmHg or ≥ 90 mmHg
    • Pulse \< 45 or > 85 beats per minute (bpm)
  6. Any clinically significant abnormalities on the 12-lead (ECG), as judged by the investigator.
  7. Any positive result at screening for serum surface antigen (HBsAg), antibody, and (HIV) antibodies.
  8. Known or suspected history of drug abuse, as judged by the investigator.
  9. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of first dosing. The period of exclusion begins 3 months after the final dose or one month after the last visit whichever is the longest.

    Note: Subjects consented and screened, but not randomized in this study or a previous phase I study, are not excluded.

  10. Plasma donation within one month of screening or any blood donation/blood loss > 500 mL during the 3 months prior to screening.
  11. History of severe allergy/ or ongoing clinically significant allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD9977.
  12. Current smokers or those who have smoked or used nicotine products within the previous 3 months.
  13. Positive screen for drugs of abuse, alcohol or cotinine at screening or for each admission to the study center.
  14. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to first dosing.
  15. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during 2 weeks prior to first dosing, or longer if the medication has a long half-life.
  16. Known or suspected history of alcohol or drug abuse or excessive intake of alcohol, as judged by the investigator.
  17. Involvement of any AstraZeneca or study site employee or their close relatives.
  18. Subjects who previously received AZD9977.
  19. Judgment by the investigator that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.
  20. Known allergy to eplerenone or fludrocortisone or any of the constituents (including lactose, which is a constituent of Florinef™).
  21. History of galactose intolerance.
  22. Any infections or at risk of infection (surgery, trauma, or significant infection) within 90 days of screening, or history of skin abscesses within 90 days of screening.
  23. Presence, history or family history of long syndrome, hypokalemia, hyperkalemia or Torsades de Pointes.
  24. Serum potassium \< 3.5 mmol/L or ≥ 5.0 mmol/L at screening or for each admission to the study center.
  25. Presence or history of active peptic ulcer.
  26. History of any psychiatric disorder (including affective, psychotic, behavioral, irritability, anxiety, sleep disturbances and cognitive disorders) which required specialist psychiatric review.
  27. Excessive intake of caffeine containing drinks or food (e.g., coffee, tea and chocolate) as judged by the investigator.
  28. Subjects who are vegans or have medical dietary restrictions (vegetarians may be included in the study).
  29. Subjects who cannot communicate reliably with the investigator.
  30. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
  31. In addition, any of the following is regarded as a criterion for exclusion from the genetic research:

    • Previous bone marrow transplant.
    • Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Treatment Sequence 1

    Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment

    Drug: AZD9977 oral suspension · Drug: AZD9977 placebo oral suspension · Drug: Fludrocortisone, tablets · Drug: Eplerenone, tablets

  • Experimental
    Treatment Sequence 2

    Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment

    Drug: AZD9977 oral suspension · Drug: AZD9977 placebo oral suspension · Drug: Fludrocortisone, tablets · Drug: Eplerenone, tablets

  • Experimental
    Treatment Sequence 3

    Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment

    Drug: AZD9977 oral suspension · Drug: AZD9977 placebo oral suspension · Drug: Fludrocortisone, tablets · Drug: Eplerenone, tablets

  • Experimental
    Treatment Sequence 4

    Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment

    Drug: AZD9977 oral suspension · Drug: AZD9977 placebo oral suspension · Drug: Fludrocortisone, tablets · Drug: Eplerenone, tablets

  • Experimental
    Treatment Sequence 5

    Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment

    Drug: AZD9977 oral suspension · Drug: AZD9977 placebo oral suspension · Drug: Fludrocortisone, tablets · Drug: Eplerenone, tablets

  • Experimental
    Treatment Sequence 6

    Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment

    Drug: AZD9977 oral suspension · Drug: AZD9977 placebo oral suspension · Drug: Fludrocortisone, tablets · Drug: Eplerenone, tablets

  • Experimental
    Treatment Sequence 7

    Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment

    Drug: AZD9977 oral suspension · Drug: AZD9977 placebo oral suspension · Drug: Fludrocortisone, tablets · Drug: Eplerenone, tablets

  • Experimental
    Treatment Sequence 8

    Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + AZD9977 Period 3: fludrocortisone + eplerenone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment

    Drug: AZD9977 oral suspension · Drug: AZD9977 placebo oral suspension · Drug: Fludrocortisone, tablets · Drug: Eplerenone, tablets

Interventions

  • AZD9977 oral suspension, single dose

  • DrugAZD9977 placebo oral suspension

    oral suspension, single dose

  • Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)

  • 100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)

06

What researchers measure

Primary outcomes

  1. Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in Eplerenone Treatment Versus a Combination Treatment of Eplerenone and AZD9977.

    The sum over the urine collection intervals of the logarithm of the urinary sodium/potassium ratio from two hours to eight hours post-dose. NOTE: Data are presented as the sum of the difference between ln(Na+) and ln(K+) over the collected intervals 2-4, 4-6 and 6-8 hours.

    Time frame: From 2 hours post dose to 8 hours post dose

Secondary outcomes

  1. Observed Maximum Concentration (Cmax) of AZD9977

    Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

    Time frame: From 2 hours post dose to 8 hours post dose

  2. Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) of AZD9977.

    Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

    Time frame: From 2 hours post dose to 8 hours post dose

  3. Area Under the Plasma Concentration-time Curve From Time Zero to t Hours After Dosing (AUC[0-t]) of AZD9977.

    Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

    Time frame: From 2 hours post dose to 8 hours post dose

  4. Time to Reach Maximum Concentration (Tmax) of AZD9977.

    Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

    Time frame: From 2 hours post dose to 8 hours post dose

  5. Terminal Half-life (t½λz) of AZD9977.

    Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

    Time frame: From 2 hours post dose to 8 hours post dose

  6. Apparent Clearance (CL/F) of AZD9977.

    Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

    Time frame: From 2 hours post dose to 8 hours post dose

  7. Apparent Volume of Distribution at Terminal Phase (Vz/F) of AZD9977.

    Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

    Time frame: From 2 hours post dose to 8 hours post dose

  8. Apparent Volume of Distribution at Terminal Phase (Vz/F) of Eplerenone.

    Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

    Time frame: From 2 hours post dose to 8 hours post dose

  9. Apparent Clearance (CL/F) of Eplerenone.

    Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

    Time frame: From 2 hours post dose to 8 hours post dose

  10. Terminal Half-life (t½λz) of Eplerenone.

    Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

    Time frame: From 2 hours post dose to 8 hours post dose

  11. Time to Reach Maximum Concentration (Tmax) of Eplerenone.

    Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

    Time frame: From 2 hours post dose to 8 hours post dose

  12. Observed Maximum Concentration (Cmax) of Eplerenone.

    Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

    Time frame: From 2 hours post dose to 8 hours post dose

  13. Area Under the Plasma Concentration-time Curve From Time Zero to t Hours After Dosing (AUC(0-t)) of Eplerenone.

    Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

    Time frame: From 2 hours post dose to 8 hours post dose

  14. Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) of Eplerenone.

    Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

    Time frame: From 2 hours post dose to 8 hours post dose

  15. Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in AZD9977 Treatment With Placebo Versus Treatment With AZD9977.

    The sum over the urine collection intervals of the logarithm of the urinary sodium/potassium ratio from two hours to eight hours post-dose. NOTE: Note: Data are presented as the sum of the difference between ln(Na+) and ln(K+) over the collected intervals 2-4, 4-6 and 6-8 hours.

    Time frame: From 2 hours post dose to 8 hours post dose

  16. Number of Participants With Clinically Significant Blood Pressure Values.

    Clinically significant blood pressure values (if available) were recorded for all participants. The systolic blood pressure (mmHg) and diastolic BP (mmHg) was obtained after each subject had rested in the supine position for at least 5 minutes and was performed in accordance with the Schedule of Assessments of study protocol. Abnormal findings in blood pressure after 10 minutes resting in the supine position was defined as following: * Systolic blood pressure (SBP) \< 90 mmHg or ≥ 140 mmHg * Diastolic blood pressure (DBP) \< 50 mmHg or ≥ 90 mmHg.

    Time frame: From screening to post-study visit, up to 10 weeks

  17. Number of Participants With Clinically Significant Pulse Rate.

    Clinically significant pulse rate (if available) was recorded for all participants in the study. The pulse was obtained after each subject had rested in the supine position for at least 5 minutes and was performed in accordance with the Schedule of Assessments of study protocol. Abnormal findings in pulse rate, after 10 minutes resting in the supine position, was defined as following: • Pulse \< 45 or \> 85 beats per minute (bpm)

    Time frame: From screening to post-study visit, up to 10 weeks

  18. Number of Participants With Clinically Significant Electrocardiogram.

    Clinically significant electrocardiogram values were recorded for all participants in the study. A 12-lead ECG was obtained after each subject had rested in the supine position for at least 10 minutes and was performed in accordance with the Schedule of Assessments of study protocol. The investigator judged the overall interpretation as normal or abnormal. If abnormal, it would have been decided as to whether or not the abnormality was clinically significant and the reason for the abnormality would have been recorded. The investigator could add extra 12-lead resting ECG safety assessments if there were any abnormal findings of if the investigator considered it was necessary for any other safety reason. These assessments would have been entered as an unscheduled assessment.

    Time frame: From screening to post-study visit, up to 10 weeks

  19. Number of Participants With Clinically Significant Physical Examination Values.

    Number of participants with clinically significant physical examination values. The complete physical examinations included an assessment of the general appearance, respiratory, cardiovascular, abdomen, skin, head, and neck (including ears, eyes, nose, mouth and throat), lymph nodes, thyroid, musculoskeletal and neurological systems. The brief physical examinations included an assessment of the general appearance, skin, abdomen, cardiovascular and respiratory systems. The results of the physical examination were listed by body system for each subject. Body weight was listed by participant and time-point. Any new or aggravated clinically relevant abnormal medical finding at a physical examination as compared with the baseline assessment were reported as an adverse event (AE).

    Time frame: From screening to post-study visit, up to 10 weeks

  20. Number of Participants With Clinically Significant Safety Laboratory Tests Values.

    Clinically significant safety laboratory test values included hematology, clinical chemistry, urinalysis and urine chemistry, including urine creatinine and uric acid measurements. Viral serology and urine drugs of abuse, alcohol and cotinine were assessed for eligibility. If deterioration in laboratory value was associated with clinical symptoms and/or signs, the symptom or sign were reported as an adverse event and the associated laboratory result was considered as additional information. Laboratory results were listed and summarized according to change from baseline and repeat/unscheduled measurements. Any out of range laboratory results were flagged in the individual listings.

    Time frame: From screening to post-study visit, up to 10 weeks

  21. Pharmacodynamics of AZD9977 Assessed by Estimating the Fractional Sodium Excretion in Urine for Each Urine Collection Time Interval.

    Pharmacodynamics of AZD9977 by assessment of fractional sodium excretion in urine for each urine collection time interval. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone.

    Time frame: From 0 to 8 hours after dosing

  22. Pharmacodynamics of AZD9977 Assessed Per Total Sodium Excreted Cumulatively and During Each of the Urine Collection Intervals.

    Pharmacodynamics of AZD9977 by assessment of total sodium excreted cumulatively and during each of the urine collection intervals. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone.

    Time frame: From 0 to 24 hours after dosing

  23. Pharmacodynamics of AZD9977 Assessed Per Fractional Potassium Excretion in Urine for Each Urine Collection Time Interval.

    Pharmacodynamics of AZD9977 assessed per fractional potassium excretion in urine for each urine collection time interval. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone

    Time frame: From 0 to 8 hours post dosing

  24. Pharmacodynamics of AZD9977 by Assessment of Total Potassium Excreted Cumulatively and During Each of the Urine Collection Intervals

    Pharmacodynamics of AZD9977 by assessment of total potassium excreted cumulatively and during each of the urine collection intervals. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone in comparison to AZD9977 placebo.

    Time frame: From 0 to 24 hours after dosing

  25. Pharmacodynamics of AZD9977 Assessed Per Urine Production for Each Urine Collection Time Interval.

    Pharmacodynamics of AZD9977 assessed per urine production for each urine collection time interval. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone.

    Time frame: From 8 hours before dosing until 24 hours after dosing

  26. Pharmacodynamics of AZD9977 by Assessment of Total Urine Volume Excreted Cumulatively and During Each of the Urine Collection Intervals

    Pharmacodynamics of AZD9977 by assessment of total urine volume excreted cumulatively and during each of the urine collection intervals. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone

    Time frame: From 8 hours before dosing until 24 hours after dosing

07

Results

Posted Mar 29, 2017

Participant flow

This study was conducted at PAREXEL Early Phase Clinical Unit London, United Kingdom

Participant flow — Overall Study
MilestoneAll Particpants
Started23
Completed23
Not completed0

Outcome measures

PrimaryPharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in Eplerenone Treatment Versus a Combination Treatment of Eplerenone and AZD9977.

The sum over the urine collection intervals of the logarithm of the urinary sodium/potassium ratio from two hours to eight hours post-dose. NOTE: Data are presented as the sum of the difference between ln(Na+) and ln(K+) over the collected intervals 2-4, 4-6 and 6-8 hours.

Time frame:
From 2 hours post dose to 8 hours post dose
Reported as:
Mean · sodium/potassium ratio
Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in Eplerenone Treatment Versus a Combination Treatment of Eplerenone and AZD9977.
sodium/potassium ratioTreatment CTreatment D
Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in Eplerenone Treatment Versus a Combination Treatment of Eplerenone and AZD9977.-0.545 ± 1.190.694 ± 1.18
Statistical analysis
  • Treatment C vs Treatment D · mixed linear model · Treatment differences: -1.258 · 90% CI -1.721 to 0.7945Analyses done using mixed linear model involving fixed effect, random effect, and a covariate.
SecondaryObserved Maximum Concentration (Cmax) of AZD9977

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

Time frame:
From 2 hours post dose to 8 hours post dose
Reported as:
Geometric mean · nmol/L
Observed Maximum Concentration (Cmax) of AZD9977
nmol/LTreatment DTreatment B
Observed Maximum Concentration (Cmax) of AZD99776238 ± 16.75816 ± 22.2
SecondaryArea Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) of AZD9977.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

Time frame:
From 2 hours post dose to 8 hours post dose
Reported as:
Geometric mean · h*nmol/L
Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) of AZD9977.
h*nmol/LTreatment DTreatment B
Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) of AZD9977.21060 ± 18.419120 ± 23.9
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to t Hours After Dosing (AUC[0-t]) of AZD9977.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

Time frame:
From 2 hours post dose to 8 hours post dose
Reported as:
Geometric mean · h*nmol/L
Area Under the Plasma Concentration-time Curve From Time Zero to t Hours After Dosing (AUC[0-t]) of AZD9977.
h*nmol/LTreatment DTreatment B
Area Under the Plasma Concentration-time Curve From Time Zero to t Hours After Dosing (AUC[0-t]) of AZD9977.19970 ± 20.318520 ± 23.6
SecondaryTime to Reach Maximum Concentration (Tmax) of AZD9977.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

Time frame:
From 2 hours post dose to 8 hours post dose
Reported as:
Median · h
Time to Reach Maximum Concentration (Tmax) of AZD9977.
hTreatment DTreatment B
Time to Reach Maximum Concentration (Tmax) of AZD9977.0.52 (0.48 to 1.02)0.50 (0.48 to 2.50)
SecondaryTerminal Half-life (t½λz) of AZD9977.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

Time frame:
From 2 hours post dose to 8 hours post dose
Reported as:
Mean · h
Terminal Half-life (t½λz) of AZD9977.
hTreatment DTreatment B
Terminal Half-life (t½λz) of AZD9977.6.753 ± 2.3226.726 ± 1.719
SecondaryApparent Clearance (CL/F) of AZD9977.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

Time frame:
From 2 hours post dose to 8 hours post dose
Reported as:
Geometric mean · L/h
Apparent Clearance (CL/F) of AZD9977.
L/hTreatment DTreatment B
Apparent Clearance (CL/F) of AZD9977.23.78 ± 18.426.20 ± 23.9
SecondaryApparent Volume of Distribution at Terminal Phase (Vz/F) of AZD9977.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

Time frame:
From 2 hours post dose to 8 hours post dose
Reported as:
Geometric mean · L
Apparent Volume of Distribution at Terminal Phase (Vz/F) of AZD9977.
LTreatment BTreatment D
Apparent Volume of Distribution at Terminal Phase (Vz/F) of AZD9977.246.7 ± 42.4220.4 ± 34.3
SecondaryApparent Volume of Distribution at Terminal Phase (Vz/F) of Eplerenone.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

Time frame:
From 2 hours post dose to 8 hours post dose
Reported as:
Geometric mean · L
Apparent Volume of Distribution at Terminal Phase (Vz/F) of Eplerenone.
LTreatment CTreatment D
Apparent Volume of Distribution at Terminal Phase (Vz/F) of Eplerenone.49.11 ± 19.244.77 ± 19.3
SecondaryApparent Clearance (CL/F) of Eplerenone.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

Time frame:
From 2 hours post dose to 8 hours post dose
Reported as:
Geometric mean · L/h
Apparent Clearance (CL/F) of Eplerenone.
L/hTreatment CTreatment D
Apparent Clearance (CL/F) of Eplerenone.10.87 ± 34.49.360 ± 35.9
SecondaryTerminal Half-life (t½λz) of Eplerenone.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

Time frame:
From 2 hours post dose to 8 hours post dose
Reported as:
Mean · h
Terminal Half-life (t½λz) of Eplerenone.
hTreatment CTreatment D
Terminal Half-life (t½λz) of Eplerenone.3.232 ± 0.83053.419 ± 0.8843
SecondaryTime to Reach Maximum Concentration (Tmax) of Eplerenone.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

Time frame:
From 2 hours post dose to 8 hours post dose
Reported as:
Median · h
Time to Reach Maximum Concentration (Tmax) of Eplerenone.
hTreatment CTreatment D
Time to Reach Maximum Concentration (Tmax) of Eplerenone.1.98 (0.48 to 3.98)2.00 (0.97 to 3.98)
SecondaryObserved Maximum Concentration (Cmax) of Eplerenone.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

Time frame:
From 2 hours post dose to 8 hours post dose
Reported as:
Geometric mean · ng/mL
Observed Maximum Concentration (Cmax) of Eplerenone.
ng/mLTreatment CTreatment D
Observed Maximum Concentration (Cmax) of Eplerenone.1557 ± 26.11729 ± 23.2
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to t Hours After Dosing (AUC(0-t)) of Eplerenone.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

Time frame:
From 2 hours post dose to 8 hours post dose
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to t Hours After Dosing (AUC(0-t)) of Eplerenone.
h*ng/mLTreatment CTreatment D
Area Under the Plasma Concentration-time Curve From Time Zero to t Hours After Dosing (AUC(0-t)) of Eplerenone.9035 ± 33.910510 ± 34.6
SecondaryArea Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) of Eplerenone.

Pre IMP dose and post IMP dose at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24 hours

Time frame:
From 2 hours post dose to 8 hours post dose
Reported as:
Geometric mean · h*ng/mL
Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) of Eplerenone.
h*ng/mLTreatment CTreatment D
Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) of Eplerenone.9199 ± 34.410680 ± 35.9
SecondaryPharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in AZD9977 Treatment With Placebo Versus Treatment With AZD9977.

The sum over the urine collection intervals of the logarithm of the urinary sodium/potassium ratio from two hours to eight hours post-dose. NOTE: Note: Data are presented as the sum of the difference between ln(Na+) and ln(K+) over the collected intervals 2-4, 4-6 and 6-8 hours.

Time frame:
From 2 hours post dose to 8 hours post dose
Reported as:
Mean · sodium/potassium ratio
Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in AZD9977 Treatment With Placebo Versus Treatment With AZD9977.
sodium/potassium ratioTreatment ATreatment B
Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in AZD9977 Treatment With Placebo Versus Treatment With AZD9977.-4.09 ± 2.11-0.694 ± 1.27
Statistical analysis
  • Treatment A vs Treatment B · mixed linear model · Treatment differences: 3.409 · 90% CI 2.946 to 3.872Analyses done using mixed linear model involving fixed effect, random effect, and a covariate.
SecondaryNumber of Participants With Clinically Significant Blood Pressure Values.

Clinically significant blood pressure values (if available) were recorded for all participants. The systolic blood pressure (mmHg) and diastolic BP (mmHg) was obtained after each subject had rested in the supine position for at least 5 minutes and was performed in accordance with the Schedule of Assessments of study protocol. Abnormal findings in blood pressure after 10 minutes resting in the supine position was defined as following: * Systolic blood pressure (SBP) \< 90 mmHg or ≥ 140 mmHg * Diastolic blood pressure (DBP) \< 50 mmHg or ≥ 90 mmHg.

Time frame:
From screening to post-study visit, up to 10 weeks
Reported as:
Number · Participants
Number of Participants With Clinically Significant Blood Pressure Values.
ParticipantsTreatment ATreatment DTreatment BTreatment C
Number of Participants With Clinically Significant Blood Pressure Values.0000
SecondaryNumber of Participants With Clinically Significant Pulse Rate.

Clinically significant pulse rate (if available) was recorded for all participants in the study. The pulse was obtained after each subject had rested in the supine position for at least 5 minutes and was performed in accordance with the Schedule of Assessments of study protocol. Abnormal findings in pulse rate, after 10 minutes resting in the supine position, was defined as following: • Pulse \< 45 or \> 85 beats per minute (bpm)

Time frame:
From screening to post-study visit, up to 10 weeks
Reported as:
Number · Participants
Number of Participants With Clinically Significant Pulse Rate.
ParticipantsTreatment ATreatment DTreatment BTreatment C
Number of Participants With Clinically Significant Pulse Rate.0000
SecondaryNumber of Participants With Clinically Significant Electrocardiogram.

Clinically significant electrocardiogram values were recorded for all participants in the study. A 12-lead ECG was obtained after each subject had rested in the supine position for at least 10 minutes and was performed in accordance with the Schedule of Assessments of study protocol. The investigator judged the overall interpretation as normal or abnormal. If abnormal, it would have been decided as to whether or not the abnormality was clinically significant and the reason for the abnormality would have been recorded. The investigator could add extra 12-lead resting ECG safety assessments if there were any abnormal findings of if the investigator considered it was necessary for any other safety reason. These assessments would have been entered as an unscheduled assessment.

Time frame:
From screening to post-study visit, up to 10 weeks
Reported as:
Number · Participants
Number of Participants With Clinically Significant Electrocardiogram.
ParticipantsTreatment ATreatment DTreatment BTreatment C
Number of Participants With Clinically Significant Electrocardiogram.0000
SecondaryNumber of Participants With Clinically Significant Physical Examination Values.

Number of participants with clinically significant physical examination values. The complete physical examinations included an assessment of the general appearance, respiratory, cardiovascular, abdomen, skin, head, and neck (including ears, eyes, nose, mouth and throat), lymph nodes, thyroid, musculoskeletal and neurological systems. The brief physical examinations included an assessment of the general appearance, skin, abdomen, cardiovascular and respiratory systems. The results of the physical examination were listed by body system for each subject. Body weight was listed by participant and time-point. Any new or aggravated clinically relevant abnormal medical finding at a physical examination as compared with the baseline assessment were reported as an adverse event (AE).

Time frame:
From screening to post-study visit, up to 10 weeks
Reported as:
Number · Participants
Number of Participants With Clinically Significant Physical Examination Values.
ParticipantsTreatment ATreatment DTreatment BTreatment C
Number of Participants With Clinically Significant Physical Examination Values.0000
SecondaryNumber of Participants With Clinically Significant Safety Laboratory Tests Values.

Clinically significant safety laboratory test values included hematology, clinical chemistry, urinalysis and urine chemistry, including urine creatinine and uric acid measurements. Viral serology and urine drugs of abuse, alcohol and cotinine were assessed for eligibility. If deterioration in laboratory value was associated with clinical symptoms and/or signs, the symptom or sign were reported as an adverse event and the associated laboratory result was considered as additional information. Laboratory results were listed and summarized according to change from baseline and repeat/unscheduled measurements. Any out of range laboratory results were flagged in the individual listings.

Time frame:
From screening to post-study visit, up to 10 weeks
Reported as:
Number · Participants
Number of Participants With Clinically Significant Safety Laboratory Tests Values.
ParticipantsTreatment ATreatment DTreatment BTreatment C
Number of Participants With Clinically Significant Safety Laboratory Tests Values.0000
SecondaryPharmacodynamics of AZD9977 Assessed by Estimating the Fractional Sodium Excretion in Urine for Each Urine Collection Time Interval.

Pharmacodynamics of AZD9977 by assessment of fractional sodium excretion in urine for each urine collection time interval. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone.

Time frame:
From 0 to 8 hours after dosing
Reported as:
Mean · % value
Pharmacodynamics of AZD9977 Assessed by Estimating the Fractional Sodium Excretion in Urine for Each Urine Collection Time Interval.
% valueTreatment ATreatment DTreatment BTreatment C
0 to 2 hours0.34 ± 0.180.33 ± 0.190.32 ± 0.090.33 ± 0.20
2 to 4 hours0.22 ± 0.150.48 ± 0.210.35 ± 0.120.37 ± 0.17
4 to 6 hours0.15 ± 0.120.58 ± 0.190.36 ± 0.130.38 ± 0.14
6 to 8 hours0.16 ± 0.150.66 ± 0.230.36 ± 0.160.48 ± 0.23
SecondaryPharmacodynamics of AZD9977 Assessed Per Total Sodium Excreted Cumulatively and During Each of the Urine Collection Intervals.

Pharmacodynamics of AZD9977 by assessment of total sodium excreted cumulatively and during each of the urine collection intervals. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone.

Time frame:
From 0 to 24 hours after dosing
Reported as:
Mean · mmol
Pharmacodynamics of AZD9977 Assessed Per Total Sodium Excreted Cumulatively and During Each of the Urine Collection Intervals.
mmolTreatment ATreatment DTreatment BTreatment C
0 to 2 hours7 ± 38 ± 67 ± 37 ± 4
2 to 4 hours12 ± 617 ± 715 ± 515 ± 7
4 to 6 hours15 ± 831 ± 1223 ± 823 ± 8
6 to 8 hours19 ± 1046 ± 1432 ± 1034 ± 10
8 to 10 hours23 ± 1263 ± 1739 ± 1247 ± 14
10 to 12 hours28 ± 1474 ± 1946 ± 1355 ± 16
12 to 14 hours32 ± 1782 ± 2251 ± 1462 ± 19
14 to 16 hours36 ± 1887 ± 2354 ± 1567 ± 21
16 to 24 hours46 ± 23103 ± 2966 ± 1979 ± 24
SecondaryPharmacodynamics of AZD9977 Assessed Per Fractional Potassium Excretion in Urine for Each Urine Collection Time Interval.

Pharmacodynamics of AZD9977 assessed per fractional potassium excretion in urine for each urine collection time interval. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone

Time frame:
From 0 to 8 hours post dosing
Reported as:
Mean · % value
Pharmacodynamics of AZD9977 Assessed Per Fractional Potassium Excretion in Urine for Each Urine Collection Time Interval.
% valueTreatment ATreatment DTreatment BTreatment C
0 to 2 hours21.72 ± 6.4922.19 ± 3.9621.14 ± 5.7421.66 ± 5.40
2 to 4 hours22.26 ± 4.2220.30 ± 4.4518.95 ± 2.7821.15 ± 5.25
4 to 6 hours14.60 ± 3.1912.49 ± 3.0412.12 ± 3.0312.48 ± 3.13
6 to 8 hours18.08 ± 4.6413.35 ± 5.6013.34 ± 4.5613.48 ± 3.55
SecondaryPharmacodynamics of AZD9977 by Assessment of Total Potassium Excreted Cumulatively and During Each of the Urine Collection Intervals

Pharmacodynamics of AZD9977 by assessment of total potassium excreted cumulatively and during each of the urine collection intervals. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone in comparison to AZD9977 placebo.

Time frame:
From 0 to 24 hours after dosing
Reported as:
Mean · mmol
Pharmacodynamics of AZD9977 by Assessment of Total Potassium Excreted Cumulatively and During Each of the Urine Collection Intervals
mmolTreatment ATreatment DTreatment BTreatment C
0 to 2 hours13.6 ± 5.614.5 ± 3.114.0 ± 5.813.7 ± 4.2
2 to 4 hours29.0 ± 9.426.7 ± 5.727.1 ± 7.727.4 ± 7.6
4 to 6 hours38.3 ± 11.135.2 ± 6.835.5 ± 8.835.9 ± 9.2
6 to 8 hours49.9 ± 13.344.4 ± 8.744.6 ± 10.445.1 ± 10.7
8 to 10 hours61.4 ± 14.754.4 ± 10.253.8 ± 11.054.9 ± 11.0
10 to 12 hours71.1 ± 15.762.1 ± 12.263.3 ± 11.464.0 ± 12.4
12 to 14 hours80.7 ± 17.571.3 ± 1572.5 ± 13.173.5 ± 12.6
14 to 16 hours87.7 ± 17.477.5 ± 15.179.2 ± 13.279.7 ± 12.9
16 to 24 hours101.8 ± 17.792.1 ± 1394.4 ± 15.595.4 ± 12.0
SecondaryPharmacodynamics of AZD9977 Assessed Per Urine Production for Each Urine Collection Time Interval.

Pharmacodynamics of AZD9977 assessed per urine production for each urine collection time interval. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone.

Time frame:
From 8 hours before dosing until 24 hours after dosing
Reported as:
Mean · mL
Pharmacodynamics of AZD9977 Assessed Per Urine Production for Each Urine Collection Time Interval.
mLTreatment ATreatment DTreatment BTreatment C
-8 to -2 hours321.4 ± 208.3309.3 ± 182.5284.5 ± 186.4294.9 ± 130.3
-2 to 0 hour303.5 ± 111.7288.6 ± 99.3274.3 ± 113.7284.5 ± 90.2
0 to 2 hour307.4 ± 78.4320.2 ± 102.6305.0 ± 89.5298.8 ± 68.9
2 to 4 hour272.2 ± 105.0236.1 ± 80.1245.6 ± 63.2272.6 ± 85.8
4 to 6 hours178.8 ± 93.8246.0 ± 115.7229.9 ± 147.7202.2 ± 99.5
6 to 8 hours216.6 ± 99.3115.7 ± 121.6273.6 ± 96.6291.5 ± 135.5
8 to 10 hours266.0 ± 125.4326.6 ± 111.7246.6 ± 103.9300.2 ± 121.1
10 to 12 hours337.1 ± 132.0361.9 ± 149.0309.0 ± 137.4324.5 ± 143.6
12 to 14 hours280.2 ± 131.0300.7 ± 141.8306.0 ± 125.4306.3 ± 152.2
14 to 16 hours357.3 ± 124.8345.9 ± 129.0326.5 ± 115.3354.2 ± 138.6
16 to 24 hours296.0 ± 184.1302.8 ± 181.1292.2 ± 164.8290.6 ± 90.2
SecondaryPharmacodynamics of AZD9977 by Assessment of Total Urine Volume Excreted Cumulatively and During Each of the Urine Collection Intervals

Pharmacodynamics of AZD9977 by assessment of total urine volume excreted cumulatively and during each of the urine collection intervals. Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone

Time frame:
From 8 hours before dosing until 24 hours after dosing
Reported as:
Mean · mL
Pharmacodynamics of AZD9977 by Assessment of Total Urine Volume Excreted Cumulatively and During Each of the Urine Collection Intervals
mLTreatment ATreatment DTreatment BTreatment C
0 to 2 hour307.4 ± 78.4320.2 ± 102.6305.0 ± 89.5298.8 ± 68.9
2 to 4 hour579.5 ± 127.2556.3 ± 126.1550.7 ± 109.2571.4 ± 128.3
4 to 6 hours758.3 ± 186.3802.2 ± 189.7780.6 ± 204.6773.6 ± 184.1
6 to 8 hours974.9 ± 235.61099.0 ± 199.11054.2 ± 201.41065.1 ± 261.1
8 to 10 hours1242.2 ± 288.91425.2 ± 235.61300.8 ± 192.61365.3 ± 261.1
10 to 12 hours1574.4 ± 329.01791.7 ± 283.61609.8 ± 264.21689.8 ± 300.9
12 to 14 hours1865.1 ± 378.92091.7 ± 354.61915.8 ± 264.21996.1 ± 330.7
14 to 16 hours2221.0 ± 340.72435.7 ± 304.42242.3 ± 233.32350.3 ± 316.6
16 to 24 hours2506.6 ± 388.62741.2 ± 293.92534.5 ± 236.32640.9 ± 347.5

Adverse events

Collected over SAEs will be collected from the signing of informed consent and AEs from randomization until post-study 5 to 7 days post-final study drug dose. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A—0/23 (0%)2/23 (8.7%)
Treatment B—0/23 (0%)3/23 (13%)
Treatment C—0/23 (0%)2/23 (8.7%)
Treatment D—0/23 (0%)4/23 (17.4%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventTreatment ATreatment BTreatment CTreatment D
HeadacheNervous system disorders1/230/230/232/23
DizzinessNervous system disorders0/231/230/230/23
Abdominal distentionGastrointestinal disorders0/231/230/230/23
Abdominal painGastrointestinal disorders0/230/231/230/23
FlatulenceGastrointestinal disorders0/231/230/230/23
NasopharyngitisInfections and infestations1/231/231/230/23
RhinorrheaRespiratory, thoracic and mediastinal disorders0/230/230/231/23
SneezingRespiratory, thoracic and mediastinal disorders1/230/230/230/23
Ocular hyperemiaEye disorders0/231/230/230/23
PyrexiaGeneral disorders0/230/230/231/23

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Particpants
Mean36 ± 8
Sex: Female, Male
Sex: Female, Male(Participants)All Particpants
Female0
Male23
08

Study locations

1 site
  • Research Site
    Harrow, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2015
First posted
Aug 26, 2015
Start
Sep 2015
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Results first posted
Mar 29, 2017
Last update
Mar 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02532998
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 26, 2015
Start date
Sep 2015
Primary completion
Dec 2015
Completion
Dec 2015
Results posted
Mar 29, 2017
Last update
Mar 29, 2017

Study contacts

Muna Albayaty, MBChB, MSc, MFPM
principal investigator · PAREXEL Early Phase Clinical Unit London

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD9977

Start the discussion